Research Collaboration and License Agreements - Additional Information (Details)	1 Months Ended						4 Months Ended	12 Months Ended
	Sep. 30, 2021 USD ($) $ / shares shares	Jul. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($) $ / shares shares	Nov. 30, 2019 $ / shares shares	Jun. 30, 2019 USD ($) shares	Nov. 30, 2017 USD ($) Target	Dec. 31, 2015 USD ($)	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) shares	Dec. 31, 2018 USD ($)	Dec. 31, 2022 USD ($)
Research Collaboration And License Agreements [Line Items]
Collaboration contract asset and other assets			$ 0					$ 12,500,000	$ 0
General and administrative								61,600,000	38,300,000	$ 27,300,000
Payments received								774,000,000
Accounts receivable			$ 1,000,000.0					15,000,000.0	1,000,000.0
Changes in deferred revenue due to additions to deferred revenue								695,500,000	$ (13,300,000)	$ 4,900,000
Revenue recognized on research collaboration and license agreements								$ 46,700,000
Common Shares
Research Collaboration And License Agreements [Line Items]
Issuance of common stock, net (in shares) | shares			6,571,428	5,227,273				3,500,000	6,600,000	6,600,000
Share price, issued and sold (in dollars per share) | $ / shares			$ 70.00	$ 22.00					$ 70.00
Pfizer, Inc.
Research Collaboration And License Agreements [Line Items]
Payments received								$ 1,200,000	$ 4,400,000		$ 28,000,000
Changes in deferred revenue due to additions to deferred revenue								742,100,000
Pfizer, Inc. | Collaboration Agreement
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved		$ 650,000,000
Collaboration agreement direct and incremental costs incurred								12,900,000
Collaboration contract asset and other assets								12,900,000
General and administrative								400,000
Pfizer, Inc. | Development Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								225,000,000
Pfizer, Inc. | Sales-based Milestone Payments
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								1,000,000,000
Payments received								0
Pfizer, Inc. | Sales-based Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								550,000,000
Pfizer, Inc. | Stock Purchase Agreement
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved		650,000,000.0
Fair value of the shares sold		$ 85,400,000
Pfizer, Inc. | Stock Purchase Agreement | Common Shares
Research Collaboration And License Agreements [Line Items]
Issuance of common stock, net (in shares) | shares	3,457,815
Share price, issued and sold (in dollars per share) | $ / shares	$ 101.22	$ 101.22
Gross proceeds	$ 350,000,000
Financial advisor fees	4,600,000
Fair value of the shares sold	$ 85,400,000
Pfizer, Inc. | Option Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								37,500,000
Pfizer, Inc. | Additional Target and Services
Research Collaboration And License Agreements [Line Items]
Accounts receivable								3,500,000
Pfizer, Inc. | Regulatory Milestone Payments
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								400,000,000
Pfizer, Inc. | Regulatory Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								1,400,000,000
Bayer A G
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved					$ 17,500,000
Bayer A G | Research Funding Payments
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved			$ 3,000,000		1,500,000			3,000,000	$ 3,000,000
Bayer A G | Research Funding Payments | Scenario Forecast
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved												$ 10,500,000
Bayer A G | Development Milestone Payments
Research Collaboration And License Agreements [Line Items]
Payments received								0
Bayer A G | Development Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved					197,500,000
Bayer A G | Sales-based Milestone Payments
Research Collaboration And License Agreements [Line Items]
Payments received								0
Bayer A G | Sales-based Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved					$ 490,000,000
Bayer A G | Stock Purchase Agreement
Research Collaboration And License Agreements [Line Items]
Fair value of the shares sold								2,900,000
Additional consideration received								2,900,000
Bayer A G | Stock Purchase Agreement | Common Shares
Research Collaboration And License Agreements [Line Items]
Issuance of common stock, net (in shares) | shares					1,346,313
Gross proceeds					$ 32,500,000
Genentech, Inc. and F. Hoffman-La Roche Ltd.
Research Collaboration And License Agreements [Line Items]
Payments received						$ 34,500,000	$ 11,000,000
Number of designated targets | Target						10
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments
Research Collaboration And License Agreements [Line Items]
Payments received								0
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								44,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Option Payments | Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								27,500,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Payments
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								52,500,000
Payments received								0
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved								60,000,000
Payments received								$ 0